ClinicalTrials.gov record
Recruiting Phase 1 Interventional

BGB-21447 (Bcl-2 Inhibitor) Combinations for Adults With Hormone-Receptor Positive (HR+)/Human Epidermal Growth Factor Receptor 2 Negative (HER2-) Metastatic Breast Cancer

ClinicalTrials.gov ID: NCT06756932

Public ClinicalTrials.gov record NCT06756932. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 8, 2026, 10:48 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-21447 (a Bcl-2 Inhibitor) Combinations for Patients With HR+/HER2- Metastatic Breast Cancer

Study identification

NCT ID
NCT06756932
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
BeOne Medicines
Industry
Enrollment
120 participants

Conditions and interventions

Interventions

  • BGB-21447 Drug
  • BGB-43395 Drug
  • Fulvestrant Drug

Drug

Eligibility (public fields only)

Age range
18 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Feb 3, 2025
Primary completion
Jul 29, 2027
Completion
Jul 29, 2027
Last update posted
Nov 9, 2025

2025 – 2027

United States locations

U.S. sites
4
U.S. states
4
U.S. cities
4
Facility City State ZIP Site status
Hoag Memorial Presbyterian Newport Beach California 92663-4162 Recruiting
University of Iowa Hospitals and Clinics Iowa City Iowa 52242-1009 Recruiting
Md Anderson Cancer Center Houston Texas 77030-3907 Recruiting
Fred Hutchinson Cancer Research Center Seattle Washington 98109-4433 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 12 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06756932, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Nov 9, 2025 · Synced May 8, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06756932 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →